446-38-8

Basic information

• Product Name: 3-Fluoro-4-nitroanisole
• Synonyms: 3-FLUORO-4-NITROANISOLE;2-Fluoro-4-methoxy-1-nitrobenzene;2-Fluoro-4-methoxynitrobenzene;2-Fluoro-4-methoxynitrobenzene, 3-Fluoro-4-nitrophenyl methyl ether;3-Fluoro-4-nitroanisole 98%;Anisole, 3-fluoro-4-nitro-
• CAS NO: 446-38-8
• Molecular Formula: C₇H₆FNO₃
• Molecular Weight: 171.13
• EINECS: 1312995-182-4
• Product Categories: blocks;FluoroCompounds;NitroCompounds;Aromatic Halides (substituted)
• Mol File: 446-38-8.mol
• Article Data: 33

Chemical Properties

• Melting Point: 57.3
• Boiling Point: 264.5 °C at 760 mmHg
• Flash Point: 113.7 °C
• Appearance: /
• Density: 1.321 g/cm³
• Vapor Pressure: 0.0159mmHg at 25°C
• Refractive Index: 1.521
• Storage Temp.: Keep Cold
• CAS DataBase Reference: 3-Fluoro-4-nitroanisole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Fluoro-4-nitroanisole(446-38-8)
• EPA Substance Registry System: 3-Fluoro-4-nitroanisole(446-38-8)

Safety Data

• Hazard Codes: Xi,C
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: 3261
• HazardClass: 8
• PackingGroup: Ⅱ
• Hazardous Substances Data: 446-38-8(Hazardous Substances Data)

Usage

General Description

3-Fluoro-4-nitroanisole is a chemical compound with the molecular formula C7H6FNO3. It is a pale yellow solid that is used in chemical research and synthesis. It is a nitro compound with a fluoro substituent and a methoxy group attached to a benzene ring. 3-Fluoro-4-nitroanisole is commonly used as a building block for the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds. It is important to handle this chemical with caution, as it may be harmful if ingested, inhaled, or absorbed through the skin, and appropriate safety precautions should be taken when working with it.

InChI:InChI=1/C7H6FNO3/c1-12-5-2-3-7(9(10)11)6(8)4-5/h2-4H,1H3

Upstream product

• 100-17-4 para-methoxynitrobenzene 
• 67-56-1 methanol 
• 446-35-5 2,4-Difluoronitrobenzene 
• 394-41-2 3-fluoro-4-nitrophenol 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 865-33-8 potassium methanolate 
• 74-88-4 methyl iodide 
• 372-20-3 3-fluorophenol 
• 124-41-4 sodium methylate 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 140381-69-7 N-(2-nitro-5-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline 
• 97655-38-4 ethyl α-cyano-5-methoxy-2-nitrobenzene acetate 
• 458-50-4 1-bromo-2-fluoro-4-methoxybenzene 
• 458-56-0 3-fluoro-4-nitroso-anisole 
• 39495-33-5 fluoro-[1,4]benzoquinone-1-oxime 
• 501-29-1 1-chloro-2-fluoro-4-methoxybenzene 
• 458-51-5 2-fluoro-1-iodo-4-methoxybenzene 
• 213627-32-8 dimethyl 2-(5-methoxy-2-nitrophenyl)malonate 
• 651729-79-2 [4-(5-methoxy-2-nitro-phenylsulfamoyl)phenoxy]acetic acid methyl ester 
• 69397-93-9 N-methyl-5-methoxy-2-nitroaniline 
• 951160-23-9 tert-butyl N-(5-methoxy-2-nitrophenyl)glycinate 
• 947258-08-4 [2-(5-Methoxy-2-nitrophenylamino)-ethyl]-carbamic acid tert-butyl ester 
• 736885-79-3 C₁₂H₁₉N₃O₃ 
• 394-41-2 3-fluoro-4-nitrophenol 

Relevant articles and documents

Efficient enantioselective total synthesis of (-)-horsfiline

A new efficient and concise enantioselective synthetic method for (-)-horsfiline is reported. (-)-Horsfiline could be obtained from diphenylmethyl tert-butyl malonate in 9 steps (32 %,>99 % ee) by using the enantioselective phase-transfer catalytic allylation (91 % ee) as the key step. This approach can be applied as a practical route for the large-scale synthesis of spirooxindole natural products, which enables a systematic investigation of their biological activity to be performed. Practical synthesis of a spirooxindole: The total synthesis of (-)-horsfiline was accomplished from diphenylmethyl tert-butylmalonate in nine steps (32 %, >99 % ee) by using a enantioselective phase-transfer catalytic allylation (91 % ee) as the key step (see scheme). Copyright

Quinoxaline compound, preparation method and application of quinoxaline compound in medicine

The invention provides a quinoxaline compound, a preparation method and application of the quinoxaline compound in medicine, and particularly relates to a quinoxaline compound with PAR4 antagonistic activity, a preparation method of the quinoxaline compound, a pharmaceutical composition containing the quinoxaline compound and application of the quinoxaline compound. Specifically, the invention provides a compound shown as a general formula I and/or II or a tautomer or pharmaceutically acceptable salt thereof, a preparation method of the compound, and application of the compound or the tautomer or the pharmaceutically acceptable salt in medicines for preventing and/or treating thromboembolic diseases.

Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold

Protease activated receptor 4 (PAR4) is an important target in antiplatelet therapy to reduce the risk of heart attack and thrombotic complications in stroke. PAR4 antagonists can prevent harmful and stable thrombus growth, while retaining initial thrombus formation, by acting on the late diffusion stage of platelet aggregation, and may provide a safer alternative to other antiplatelet agents. To date, only two PAR4 antagonists, BMS-986120 and BMS-986141 have entered clinical trials for thrombosis. Thus, the development of a potent and selective PAR4 antagonist with a novel chemotype is highly desirable. In this study, we explored the activity of quinazolin-4(3H)-one-based PAR4 antagonists, beginning with their IDT analogues. By repeated structural optimisation, we developed a series of highly selective PAR4 antagonists with nanomolar potency on human platelets. Of these, 13 and 30g, with an 8-benzo[d]thiazol-2-yl-substituted quinazolin-4(3H)-one structure, showed optimal activity (h. PAR4-AP PRP IC50 = 19.6 nM and 6.59 nM, respectively) on human platelets. Furthermore, 13 and 30g showed excellent selectivity for PAR4 versus PAR1 and other receptors (IC50s > 10 μM) on human platelets. And 13 and 30g were lack of cross-reactivity for PAR1 or PAR2 (PAR1 AP FLIPR IC50 > 3162 nM, PAR2 AP FLIPR IC50 > 1000 nM) in the calcium mobilization assays. Metabolic stability assays and cytotoxicity tests of 13 and 30g indicated that these compounds could sever as promising drug candidates for the development of novel PAR4 antagonists. In summary, the quinazolin-4(3H)-one-based analogues are the first reported chemotypes with excellent activity and selectivity against PAR4, and, in the current study, we expanded the structural diversity of PAR4 antagonists. The two compounds, 13 and 30g, found in our study could be promising starting points with great potential for further research in antiplatelet therapy.